|
|
Congestive Heart Failure: Worldwide Drug and Medical Device MarketsPublished by: Kalorama Information Published: Mar. 1, 2002 - 334 Pages Special Offer. Now 25% off the original price of $3500.Table of Contents Chapter One: Executive Summary
Background Scope and Methodology Size and Growth of Market Market Trends The Nature of the Industry The New Technologies Chapter Two: Overview of Congestive Heart Failure
Background Pathophysiology Conditions Leading to Congestive Heart Failure Diagnosis of Congestive Heart Failure Classification of Patients Epidemiology Chapter Three: Treatment of Congestive Heart Failure
Pharmacologic Therapy Congestive Heart Failure Devices Chapter Four: Congestive Heart Failure Patient Management
Guidelines for Management of Chronic Heart Failure Strategies to Maintain Quality Patient Care and Contain Costs Chapter Five: Emerging Technologies To Treat Congestive Heart Failure Pharmacologic Treatments Medical Devices Biotechnology Chapter Six: Company Profiles Abiomed, Inc. Acorn Cardiovascular, Inc. Actelion Ltd. Arrow International Bioheart, Inc. CardioEnergetics, Inc. CV Therapeutics GenVec, Inc. Geron Corporation Guidant Corporation MediGene AG MedQuest Products, Inc. Medtronic, Inc. MicroMed Technology, Inc. Myocor, Inc. Myogen St. Jude Medical Somanetics Corporation Texas Biotechnology Corporation Thoratec Corporation Chapter Seven: Conclusions and Strategic Implications Prevention Over Treatment Medical Approaches Over Surgical Approaches Accelerating Device Development Device Competition Heats Up Big Pharma Still Dominant Biotech Emerges Transplant Alternatives on the Way Drug Market Outpaces Epidemiology Appendix A: Glossary Appendix B: Company Directory List of Exhibits Chapter One: Executive Summary Figure 1-1: Incidence of Congestive Heart Failure Cases in the Major World Healthcare Markets, 2000-2008 Figure 1-2: Prevalence of Congestive Heart Failure Cases in the Major World Healthcare Markets, 2000-2008 Figure 1-3: The Total Market for Congestive Heart Failure Therapeutics in the Major World Healthcare Markets: 2000-2008 Table 1-1: Estimated Market Sizes for CHF Pharmaceuticals in the Major World Healthcare Markets, 2000-2008 Table 1-2: Estimated Market Sizes for CHF Devices in the Major World Healthcare Markets, 2000-2008 Figure 1-4: Trending in the World’s Major Congestive Heart Failure Therapy Markets (Total), 2000-2008 Figure 1-5: Composition of the Markets for Congestive Heart Failure Therapeutics by Product Classification: 2000-2008 Table 1-3: Key Competitors in Congestive Heart Failure Therapeutics Chapter Two: Overview of Congestive Heart Failure Table 2-1: Common Contributors to Congestive Heart Failure Figure 2-1: Incidence and Prevalence of Congestive Heart Failure In the World’s Major Healthcare Markets, 2000-2008 Figure 2-2: Incidence Rates of Congestive Heart Failure in the Major World Healthcare Markets, 2000-2008 Figure 2-3: Prevalence Rates of Congestive Heart Failure in the Major World Healthcare Markets, 2000-2008 Figure 2-4: Percentage Breakdown of Deaths from Cardiovascular Diseases: 1999 Table 2-2: Incidence and Prevalence of CHF in the United States: 2000-2008 Figure 2-5: Incidence and Prevalence of CHF in the United States: 2000-2008 Figure 2-6: Prevalence of Congestive Heart Failure in the United States by Age and Sex: 1988-1994 Figure 2-7: The Distribution of Congestive Heart Failure Among the Five Major European Healthcare Markets, 2002 Table 2-3: Incidence and Prevalence of CHF in the Major European Healthcare Markets, 2000-2008 Figure 2-8: Incidence and Prevalence of CHF in the Major European Healthcare Markets, 2000-2008 Table 2-4: Incidence and Prevalence of CHF in the Japanese Healthcare Market, 2000-2008 Figure 2-9: Incidence and Prevalence of CHF in the Japanese Healthcare Market, 2000-2008 Chapter Three: Management of Congestive Heart Failure Table 3-1: Therapeutic Strategies for Symptomatic Congestive Heart Failure Table 3-2: Pharmacologic Response to the Pathophysiology of Cardiac Performance Table 3-3: Common ACE Inhibitors Available for the Treatment of CHF Table 3-4: Common Angiotensin II Receptor Antagonists Available for the Treatment of CHF Table 3-5: Common â-Receptor Antagonists Available for the Treatment of CHF Table 3-6: Common Diuretics Available for the Treatment of CHF Table 3-7: Common Inotropic Drugs Available for the Treatment of CHF Table 3-8: Common Vasodilators Available for the Treatment of CHF Table 3-9: Estimated Historic and Forecast Markets for CHF Pharmaceuticals in the Major World Healthcare Markets, 2000-2008 Figure 3-1: Trending in the Estimated Historic and Forecast Markets for CHF Pharmaceuticals in the Major World Healthcare Markets, 2000-2008 Figure 3-2: Distribution of the Estimated Historic and Forecast Markets for CHF Pharmaceuticals in the Major World Healthcare Markets, 2000-2008 Table 3-10: Estimated Historic and Forecast Markets for CHF Pharmaceuticals in the United States, 2000-2008 Figure 3-3: Trending in the Estimated Historic and Forecast Markets for CHF Pharmaceuticals in the United States, 2000-2008 Figure 3-4: Distribution of the Estimated Historic and Forecast Market Segments for CHF Pharmaceuticals in the United States, 2000-2008 Table 3-11: Estimated Historic and Forecast Markets for CHF Pharmaceuticals in the Major European Markets: 2000-2008 Figure 3-5: Trending in the Estimated Historic and Forecast Markets for CHF Pharmaceuticals in the Major European Markets, 2000-2008 Figure 3-6: Distribution of the Estimated Historic and Forecast Market Segments for CHF Pharmaceuticals in the Major European Markets, 2000-2008 Table 3-12: Estimated Historic and Forecast Markets for CHF Pharmaceuticals in Japan, 2000-2008 Figure 3-7: Trending in the Estimated Historic and Forecast Markets For CHF Pharmaceuticals in the Major Japanese Markets, 2000-2008 Figure 3-8: Distribution of the Estimated Historic and Forecast Market Segments for CHF Pharmaceuticals in the Major Japanese Markets, 2000-2008 Table 3-13: Companies Actively Addressing the CHF Pharmaceutical Markets Table 3-14: Key Competitors in the CHF Pharmaceutical Arena Table 3-15: Guidelines for the Choice of Pacemaker Generator In Selected Indications for Pacing Table 3-16: Biventricular Pacemakers for CHF Therapy Table 3-17: Cardioverter/Defibrillators (ICD) Available for Use in the Treatment of CHF Table 3-18: Ventricular Assist Devices (VADs) On the Market and in Development Table 3-19: The Estimated Markets for Devices to Treat CHF in the Major World Healthcare Markets by Geographic Segment Figure 3-9: Trending in the Estimated Markets for Devices to Treat CHF In the Major World Healthcare Markets by Geographic Segment Figure 3-10: Distribution of the Estimated Markets for Devices to Treat CHF in the Major World Healthcare Markets by Geographic Segment Table 3-20: Estimated Markets for Devices to Treat CHF in the Major World Healthcare Markets by Geographic Segment Figure 3-11: Trending in the Estimated Markets for Devices to Treat CHF in the Major World Healthcare Markets by Device Segment Figure 3-12: Distribution of the Estimated Markets for Devices to Treat CHF in the Major World Healthcare Markets by Device Segment Table 3-21: The Estimated Markets for Devices to Treat CHF in the United States Healthcare Market by Device Segment Figure 3-13: Trending in the Estimated Markets for Devices to Treat CHF in the United States Healthcare Market by Device Segment Figure 3-14: Distribution of the Estimated Markets for Devices to Treat CHF in the United States Healthcare Market by Device Segment Table 3-22: The Estimated Markets for Devices to Treat CHF in the Major European Healthcare Markets by Device Segment Figure 3-15: Trending in the Estimated Markets for Devices to Treat CHF in the Major European Healthcare Markets by Device Segment Figure 3-16: Distribution of the Estimated Markets for Devices to Treat CHF in the Major European Healthcare Markets By Device Segment Table 3-23: The Estimated Markets for Devices to Treat CHF in the Japanese Healthcare Market by Device Segment Figure 3-17: Trending in the Estimated Markets for Devices to Treat CHF in the Japanese Healthcare Market by Device Segment Figure 3-18: Distribution of the Estimated Markets for Devices to Treat CHF in the Japanese Healthcare Market by Device Segment Chapter Four: Congestive Heart Failure Patient Management Figure 4-1: ACC/AHA Guideline Summary for Recommended Therapy of Congestive Heart Failure by Stage of the Disease Table 4-1: ACC/AHA Staging of Congestive Heart Failure Table 4-2, 2001 ACC/AHA Guidelines for Evaluation and Treatment for Congestive Heart Failure Chapter Five: Emerging Technologies To Treat CHF Table 5-1: New Drugs in Development for the Treatment of Congestive Heart Failure Table 5-2: Medical Devices in Clinical Trials for the Treatment of Congestive Heart Failure Table 5-3: Biotechnology-Based Therapeutics for Congestive Heart Failure in Development AbstractApproximately 23 million people worldwide are afflicted with congestive heart failure (CHF), and 2 million new cases of CHF are diagnosed each year worldwide. In contrast to other cardiovascular disorders that have actually declined during the past few decades, the incidence of heart failure is on the rise. It is, in fact, the most rapidly growing cardiovascular disorder in the United States.There is no cure for CHF short of a heart transplant. Although advances in pharmacology have led to better treatment, 50% of the patients with the most advanced stage of heart failure die within a year. Typically, heart failure patients receive several chronic oral therapies, including diuretics, ACE inhibitors, beta-blockers and inotropic agents. However, a new class of CHF drugs created by biotechnology companies will soon be on the market. These new drugs will lead the way to a revolution in the treatment of CHF and could spark a biotechnology boom similar to the AIDS breakthroughs of 1996 and 1997. A majority of patients are treated with drug therapy, but for patients with advanced CHF, device-based therapy or transplantation are their only alternatives. A large number of patients with advanced CHF have received left ventricular assist devices, and a number of promising technologies, including biventricular pacing and defibrillators, ventricular remodeling, and ventricular assist devices represent exciting, growing markets.
Kalorama’s Congestive Heart Failure: Worldwide Drug and Medical Device Markets thoroughly reviews the current state of the markets in this expanding field, including developments in drug therapy and technological advances in the device markets.
|
|
|||
|
About MarketResearch.com
|
||||